Free Trial
NASDAQ:BNTX

BioNTech (BNTX) Stock Price, News & Analysis

$105.00
+5.73 (+5.77%)
(As of 09/12/2024 ET)
Today's Range
$95.48
$105.07
50-Day Range
$78.36
$105.00
52-Week Range
$76.53
$117.98
Volume
1.84 million shs
Average Volume
715,351 shs
Market Capitalization
$24.96 billion
P/E Ratio
210.00
Dividend Yield
N/A
Price Target
$109.09

BioNTech MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
3.9% Upside
$109.09 Price Target
Short Interest
Healthy
1.09% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.66mentions of BioNTech in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.80) to ($2.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.47 out of 5 stars

Medical Sector

706th out of 936 stocks

Biological Products, Except Diagnostic Industry

125th out of 155 stocks

BNTX stock logo

About BioNTech Stock (NASDAQ:BNTX)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

BNTX Stock Price History

BNTX Stock News Headlines

syringe and vaccine in hand
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze? (BNTX)
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.
Novavax stock price forecast
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp? (BNTX)
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases.
Blacklisted by AI: Guilty Until Proven Innocent!
AI has garnered a lot of attention post the launch of ChatGPT, and rightly so. But here's a chilling fact a lot of people don't know: For decades, agencies like the NSA have been using AI to illegally snoop into the private lives of millions of Americans.
Promising BNT327 Data Bolsters BioNTech’s Buy Rating, With a Target of $171
BioNTech SE ADR rises Tuesday, still underperforms market
BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
BioNTech Sees Unusually Large Options Volume (NASDAQ:BNTX)
Blacklisted by AI: Guilty Until Proven Innocent!
AI has garnered a lot of attention post the launch of ChatGPT, and rightly so. But here's a chilling fact a lot of people don't know: For decades, agencies like the NSA have been using AI to illegally snoop into the private lives of millions of Americans.
J.P. Morgan Sticks to Its Sell Rating for BioNTech SE (BNTX)
Morgan Stanley Sticks to Its Hold Rating for BioNTech SE (BNTX)
See More Headlines
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/05/2024
Today
9/12/2024
Next Earnings (Estimated)
11/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BNTX
Employees
6,133
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$109.09
High Stock Price Target
$171.00
Low Stock Price Target
$85.00
Potential Upside/Downside
+13.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$1.01 billion
Pretax Margin
-8.75%

Debt

Sales & Book Value

Annual Sales
$2.69 billion
Cash Flow
$5.42 per share
Book Value
$92.17 per share

Miscellaneous

Free Float
192,083,000
Market Cap
$22.88 billion
Optionable
Optionable
Beta
0.23

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Ugur Sahin M.D. (Age 59)
    Co-Founder, CEO & Chair of the Management Board
    Comp: $1.25M
  • Dr. Ozlem Tureci M.D. (Age 57)
    Co-Founder, Chief Medical Officer & Member of Management Board
    Comp: $823.67k
  • Mr. Jens H. Holstein (Age 61)
    CFO & Member of Management Board
    Comp: $1.44M
  • Dr. Sierk Poetting Ph.D. (Age 51)
    MD, COO & Member of Management Board
    Comp: $846.46k
  • Mr. Ryan Richardson (Age 45)
    Chief Strategy Officer, MD & Member of Management Board
    Comp: $1.04M
  • Mr. Sean Marett (Age 59)
    Chief Business Officer, Chief Commercial Officer & Member of Management Board
    Comp: $817.16k
  • Dr. James Timothy Patrick Ryan Ph.D. (Age 49)
    Chief Legal Officer & Member of the Management Board
    Comp: $612.05k
  • Mr. Zach Taylor
    Senior Vice President of Corporate Development & Strategy
  • Dr. Katalin Kariko Ph.D.
    Senior VP & External Consultant for RNA Protein Replacement Therapies
  • Dr. Oliver Henning Ph.D.
    Senior Vice President of Operations

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in BioNTech SE:

  • BioNTech SE has shown resilience in the market despite recent challenges, indicating strong potential for growth.
  • The company's innovative approach to developing immunotherapies for cancer and infectious diseases positions it well in the biotechnology sector.
  • Recent institutional investments in BioNTech SE, such as Primecap Management Co. CA boosting its stake, reflect confidence from major players in the market.
  • With a market capitalization of $20.25 billion, BioNTech SE is a significant player in the industry, offering stability and growth opportunities.
  • The company's focus on cutting-edge research and development could lead to breakthrough treatments, driving stock price appreciation.

Cons

Investors should be bearish about investing in BioNTech SE for these reasons:

  • The company's recent earnings report showed a significant miss on EPS, which may raise concerns about its financial performance.
  • BioNTech SE's revenue decline of 23.3% compared to the previous year indicates potential challenges in maintaining growth.
  • Despite institutional investments, the stock's price-to-earnings ratio of 170.38 may be considered high, posing a risk for investors.
  • The company's net margin of 4.01% suggests relatively low profitability compared to industry peers, impacting potential returns for investors.
  • Analysts forecasting negative EPS for the current fiscal year could lead to short-term volatility in the stock price, affecting investor confidence.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 8, 2024. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BNTX Stock Analysis - Frequently Asked Questions

How have BNTX shares performed this year?

BioNTech's stock was trading at $105.54 on January 1st, 2024. Since then, BNTX stock has decreased by 0.5% and is now trading at $105.00.
View the best growth stocks for 2024 here
.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) issued its quarterly earnings data on Monday, August, 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by $1.34. BioNTech's quarterly revenue was down 23.3% on a year-over-year basis.

What is Ugur Sahin's approval rating as BioNTech's CEO?

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

Does BioNTech have any subsidiaries?

BioNTech subsidiaries include these companies: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and more.

When did BioNTech IPO?

BioNTech (BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

Who are BioNTech's major shareholders?

BioNTech's top institutional shareholders include Baillie Gifford & Co. (3.48%), Primecap Management Co. CA (2.01%), Deerfield Management Company L.P. Series C (0.25%) and Candriam S.C.A. (0.24%).

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX) and Gilead Sciences (GILD).

This page (NASDAQ:BNTX) was last updated on 9/12/2024 by MarketBeat.com Staff

From Our Partners